Gentamicin sulfate in sodium chloride 0.9% in plastic container?

Gentamicin Sulfate – 0.9 % Sodium Chloride (Plastic Container)
(A typical ready‑to‑inject formulation of the aminoglycoside antibiotic)

---

1. Product Overview

Item	Detail
Active Ingredient	Gentamicin sulfate (aminoglycoside)
Excipient	0.9 % Sodium chloride (0.9 % NaCl, isotonic)
Concentration	40 mg/mL (most common; some compacts use 80 mg/mL or 120 mg/mL)
Volume per vial	5 mL (200 mg) – most common; other volumes: 1 mL (40 mg), 10 mL (400 mg)
Packaging	Plastic vial (polyethylene or polypropylene), often 100 mL or 250 mL “syringe‑fill” bag for high‑volume preparations
Stability	Store 2 – 8 °C; protect from light; shelf life 30 days (unopened) or 12 months (after opening, with preservative)
Compatibility	Compatible with most IV solutions; avoid mixing with solutions containing high concentrations of dextrose or potassium, which can precipitate

---

2. Mechanism of Action

Gentamicin binds the 30S subunit of bacterial ribosomes, inhibiting protein synthesis and causing a misreading of mRNA. It is bactericidal and is most effective against aerobic Gram‑negative organisms; it also has activity against some Gram‑positive cocci and anaerobes when used in combination with other agents.

---

3. Clinical Indications

Infection	Typical Use	Example Dosing (Adult)
Gram‑negative infections (e.g., urinary tract, intra‑abdominal, bloodstream, meningitis)	IV or IM	5–7 mg/kg/day, divided q8‑12 h (total daily dose 2.5–5 mg/kg)
Pneumonia	IV, sometimes IM	3–5 mg/kg/day, q8‑12 h
Endocarditis	IV, 5–7 mg/kg/day, q12 h (higher loading dose 5 mg/kg)
Ocular infections	Ophthalmic solution	0.3 % (10 mg/mL) diluted to 0.3 % (10 mg/mL) – 3–4 drops q4‑6 h
Skin/soft‑tissue	Topical (cream/gel)	0.3 % (10 mg/mL) applied 3–4 × daily
Bone/Joint	IV or intra‑articular	5–7 mg/kg/day, q8‑12 h

Note: Dosing in neonates, infants, and patients with renal impairment must be adjusted; therapeutic drug monitoring (TDM) is strongly recommended.

---

4. Pharmacokinetics (Adult)

Parameter	Typical Value
Absorption	IV/IM: 100 %
Distribution	Volume of distribution ~0.4 L/kg; limited CNS penetration
Half‑life	2–2.5 h (renal elimination)
Metabolism	None significant
Excretion	Primarily renal (70–80 %)

Important: The drug is concentration‑dependent; peak serum levels (Cmax) correlate with efficacy, while trough levels (Cmin) correlate with toxicity. Target peaks 2–10 mg/L, troughs <1 mg/L.

---

5. Contraindications

• Known hypersensitivity to gentamicin or other aminoglycosides.
• Pre‑existing irreversible sensorineural hearing loss or vestibular dysfunction.
• Severe renal impairment (creatinine clearance <10–20 mL/min) without dose adjustment.
• Severe metabolic acidosis (pH < 7.3) – decreases renal clearance.

---

6. Precautions / Warnings

Issue	Details
Ototoxicity	Monitor hearing and balance. Avoid concurrent ototoxic drugs (e.g., loop diuretics, furosemide).
Nephrotoxicity	Monitor serum creatinine and BUN daily; adjust dose based on renal function.
Neurotoxicity	May cause neuromuscular blockade; avoid with depolarizing muscle relaxants.
Pregnancy	Category C – use only if benefits outweigh risks; avoid during first trimester if possible.
Breastfeeding	Limited data; advise caution or discontinue breastfeeding.
Drug interactions	- Aminoglycosides + loop diuretics, NSAIDs, or other nephrotoxic drugs increase risk. - Antiepileptics (phenytoin) may reduce drug levels.
Renal Replacement Therapy	Dose adjustment required; monitor drug levels.

---

7. Adverse Reactions

Class	Frequency
Ototoxicity	1–5 % (dose‑related)
Nephrotoxicity	2–10 % (dose‑related)
Allergic	1 % (rash, urticaria, anaphylaxis)
Gastrointestinal	Nausea, vomiting, diarrhea (rare)
Neuromuscular	Rare but significant (paralysis, respiratory failure)
Other	Hypotension, flushing, headache

---

8. Special Populations

Group	Considerations
Neonates / Infants	5–7 mg/kg/day, q12 h; monitor troughs <1 mg/L.
Elderly	Reduced renal clearance → lower doses, longer dosing intervals.
Renal impairment	Dose reduction based on clearance; use TDM.
Hepatic impairment	Minimal effect; no dose adjustment needed.
Obesity	Use actual body weight; adjust if >10 % excess weight.

---

9. Administration Tips (IV)

1. Dilution – Dilute 1–2 mL of vial in 10 mL of normal saline or 0.9 % NaCl to reduce irritation.
2. Infusion rate – 30–60 min for 0.5 mL/​kg or 10 mL bolus; slower rate (60–120 min) for larger volumes to avoid phlebitis.
3. Avoid mixing with high‑potassium solutions, dextrose 5 % (prevents precipitation).
4. Compatibility – Check compatibility tables before mixing with other IV drugs.
5. Documentation – Record dose, time, infusion rate, and any adverse reactions.

---

10. Storage & Handling

• **Temperature